Phase II Evaluation of 3-Day Topotecan with Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer

This publication has 21 references indexed in Scilit:

• Topotecan (hycamptin) and topotecan-containing regimens in the treatment of hematologic malignancies.
  Annals of the New York Academy of Sciences, 2006
• Cancer Statistics, 2001
  CA: A Cancer Journal for Clinicians, 2001
• Phase 2 Evaluation of Topotecan Administered on a 3-Day Schedule in the Treatment of Platinum- and Paclitaxel-Refractory Ovarian Cancer
  Gynecologic Oncology, 2000
• Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
  Journal of Clinical Oncology, 1998
• Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines
  Anti-Cancer Drugs, 1998
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996
• Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.
  Journal of Clinical Oncology, 1995
• Topoisomerase I inhibitors: topotecan and irenotecan
  Cancer Treatment Reviews, 1994
• Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating Factor
  JNCI Journal of the National Cancer Institute, 1993
• Optimal two-stage designs for phase II clinical trials
  Controlled Clinical Trials, 1989